首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1735698

全球人類疫苗佐劑市場規模（按類型、給藥途徑、應用、區域範圍）預測（至 2025 年）

Global Human Vaccine Adjuvants Market Size By Type, By Route Of Administration, By Application, By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

人用疫苗佐劑的市場規模及預測

2024 年人類疫苗佐劑市場規模價值 15.9 億美元，預計到 2032 年將達到 45 億美元，預測期內（2026-2032 年）的複合年成長率為 12.1%。

推動全球人類疫苗佐劑市場的因素

人類疫苗佐劑市場的促進因素可能受到多種因素的影響。這些因素包括：

感染疾病爆發：感染疾病持續對世界各地的公共衛生構成嚴重威脅，增加了對疫苗的需求，這就是為什麼需要佐劑來提高疫苗接種的有效性。
疫苗研發投入增加：新冠疫情等疫情爆發後，各國政府、私人機構及製藥公司紛紛增加對疫苗研發的投資。由於這些投資的增加，用於增強疫苗效力的佐劑的需求也隨之增加。
技術發展：免疫學和技術的突破帶來了能夠引發更強免疫反應的創新佐劑，增加了這些產品的市場需求。
老年人口不斷增加：隨著老齡化成長，老年人的免疫功能下降，更容易感染疾病。因此，人們越來越重視開發針對帶狀皰疹、肺炎和流感等疾病的疫苗，並且需要針對老年人更有效的佐劑。
擴大免疫接種計劃：為了阻止感染疾病的傳播，各國政府和國際組織正在實施廣泛的免疫接種計劃，尤其是在開發中國家。因此，需要疫苗佐劑來資助這些工作。
提高公眾對預防性醫療保健的認知：隨著公眾對疫苗接種在疾病預防中的價值的認知不斷提高，公眾對疫苗的接受度也在不斷提高，從而對增強免疫反應和提高疫苗有效性的佐劑的需求也隨之增加。
加強大流行病防範：COVID-19 和最近的大流行凸顯了防範新發感染疾病的重要性，導致對佐劑研究和疫苗開發的投資增加，以便能夠快速應對未來可能爆發的感染疾病。
監管支援：監管機構逐漸意識到佐劑在疫苗研發中的價值，並正在加快佐劑疫苗的核准流程，獎勵製藥公司投入資源進行佐劑的研發，有助於擴大市場。

限制全球人類疫苗佐劑市場的因素

人類疫苗佐劑市場面臨諸多限制與挑戰，包括：

監管挑戰：佐劑受到各國政府的嚴格審查，因為它們會影響疫苗的安全性和有效性。滿足監管核准標準可能耗時耗力，成本高昂，這可能會阻礙新業務進入市場。
安全問題：有安全問題的佐劑在疫苗製劑中可能較少使用。佐劑可能引起注射部位的不良反應或局部不適，這可能會阻礙患者和醫護人員的接種。
成本限制：佐劑的開發和生產成本可能很高，尤其是獨特或專有配方。昂貴的疫苗生產成本可能高成本，這限制了某些患者群體和資源匱乏地區的疫苗供應。
採用率有限：由於傳統的非佐劑疫苗可能已在市場上廣泛普及，新的佐劑疫苗可能難以廣泛認可。除非有確鑿證據顯示新產品的安全性或有效性有所提高，否則病患和醫護人員可能不願意轉向新產品。
智慧財產權問題：添加劑技術的智慧財產權可能會使新競爭對手難以進入市場。專利糾紛、專有配方和授權協議可能會抑制市場競爭和創新。
生產挑戰：擴大佐劑疫苗的生產規模可能相當具有挑戰性，需要特定的設施和生產技術。佐劑疫苗的供應和成本可能會受到生產限制（包括產能有限和生產延遲）的影響。
公眾輿論與採用：佐劑的採用和吸收可能會受到公眾對佐劑的看法的影響，而公眾對疫苗的猶豫、虛假資訊等因素則會影響佐劑的採用和吸收。透過教育和溝通舉措解決安全性和有效性問題對於佐劑市場的繁榮至關重要。
全球健康差距：不同地區和社會經濟群體在醫療保健和免疫接種方面的差異可能會加劇佐劑疫苗的市場限制。為了促進市場成長，必須透過集中定價、協調監管和增加基礎設施支出來解決這些差距。

Growing Prevalence of Infectious illnesses: Vaccine demand is rising as infectious illnesses continue to pose serious risks to public health around the world. This is the reason why adjuvants for vaccinations are necessary to increase their effectiveness.
Increasing Vaccine Development Investments: Following pandemics such as COVID-19, governments, private groups, and pharmaceutical firms are making significant investments in vaccine research and development. Adjuvants that can increase vaccine efficacy are in higher demand as a result of this increasing spending.
Technological Developments: Immunology and technological breakthroughs have produced innovative adjuvants that can elicit more robust immune responses, increasing the market's demand for these goods.
Growing Senior Population: As immune systems deteriorate with age, older people are more vulnerable to infectious diseases. Consequently, there is a growing emphasis on creating vaccinations against illnesses like shingles, pneumonia, and influenza, which need adjuvants to be more effective against older persons.
Extending immunization Programs: To stop the spread of infectious illnesses, particularly in developing nations, governments and international organizations are putting in place broad immunization programs. As a result, there is a need for vaccine adjuvants to fund these initiatives.
Growing Public Awareness of Preventive Healthcare: As public awareness of the value of vaccination in illness prevention rises, so does public acceptance of vaccines. Adjuvants that can boost immune responses and increase vaccine effectiveness are in high demand as a result.
Increase in Pandemic Preparedness: COVID-19 and other recent pandemics have brought attention to the significance of being ready for newly developing infectious illnesses. Investments in adjuvant research and vaccine development have increased as a result, enabling quick reactions to potential outbreaks in the future.
Regulatory Support: Regulatory bodies are expediting the approval procedures for adjuvanted vaccines as they become more aware of the value of adjuvants in vaccine development. This propels market expansion by incentivizing pharmaceutical companies to allocate resources on adjuvant research and development.

Global Human Vaccine Adjuvants Market Restraints

Several factors can act as restraints or challenges for the Human Vaccine Adjuvants Market. These may include:

Regulatory Difficulties: Because adjuvants may affect the safety and effectiveness of vaccines, they are closely inspected by the government. It might take time and money to comply with regulatory criteria for approval, which prevents new businesses from entering the market.
Safety Issues: Adjuvants that raise safety issues may not be used as much in vaccine formulations. Adjuvants have the potential to elicit negative reactions or localized discomfort at the injection site, which could make patients and healthcare providers hesitant.
Cost Restrictions: Adjuvant development and production can be expensive, especially for unique or proprietary formulas. Expensive vaccinations may be produced at high costs, which could restrict availability for some patient populations or in environments with limited resources.
Limited Adoption: It may be difficult for newly adjuvanted vaccinations to become widely accepted because traditional vaccines without adjuvants may already be well-established in the market. Patients and healthcare professionals could be hesitant to move to new products unless there is compelling proof of increased safety or efficacy.
Intellectual Property Problems: Adjunctive technology' intellectual property rights may make it difficult for new competitors to enter the market. Patent conflicts, proprietary formulae, and licensing agreements can stifle market competition and innovation.
Manufacturing Difficulties: Increasing the production of vaccines with adjuvants can be difficult and necessitate certain facilities and manufacturing techniques. Adjuvanted vaccine supply and cost may be impacted by manufacturing limitations such as capacity limitations or production delays.
Public opinion and adoption: Adjuvants' adoption and uptake can be impacted by the public's opinion of them, which can be shaped by things like vaccine hesitancy or disinformation. For the adjuvant market to flourish, it is imperative that safety and efficacy issues are addressed through education and communication initiatives.
Global Health Inequities: Market constraints for adjuvanted vaccines may be made worse by differences in the availability of healthcare and vaccinations among geographic or socioeconomic groups. For the market to grow, these disparities must be addressed by focused pricing tactics, harmonized regulations, and infrastructure spending.

Global Human Vaccine Adjuvants Market Segmentation Analysis

The Global Human Vaccine Adjuvants Market is Segmented on the basis of Type, Route of Administration, Application, and Geography.

Human Vaccine Adjuvants Market, By Type

Aluminum Salts: Traditional adjuvants widely used in vaccines to enhance immune response and improve antigen persistence. Examples include aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
Oil-based Adjuvants: Lipid-based formulations that promote antigen uptake and activation of immune cells. Examples include MF59 (squalene oil-in-water emulsion) and AS03 (squalene-based adjuvant system).
Mineral Salts: Adjuvants composed of mineral salts such as calcium phosphate, calcium carbonate, and magnesium hydroxide, which enhance antigen presentation and stimulate immune response.
Adjuvant Systems: Combination adjuvant formulations designed to elicit specific immune responses and enhance vaccine efficacy. Examples include AS04 (aluminum hydroxide with monophosphoryl lipid A) and AS01 (liposome-based adjuvant containing MPL and QS-21).

Human Vaccine Adjuvants Market, By Route of Administration

Intramuscular (IM) Administration: Vaccines administered via injection into the muscle, commonly utilizing adjuvants to enhance immunogenicity and promote long-lasting immunity.
Subcutaneous (SC) Administration: Vaccines injected under the skin, often incorporating adjuvants to improve antigen delivery and stimulate immune response.
Intradermal (ID) Administration: Vaccines administered directly into the skin using a microneedle or other delivery device, with adjuvants facilitating antigen uptake by immune cells in the dermis.

Human Vaccine Adjuvants Market, By Application

Infectious Diseases Vaccines: Adjuvants used in vaccines against infectious diseases such as influenza, hepatitis B, human papillomavirus (HPV), and meningococcal disease, aiming to induce protective immunity and prevent infection.
Cancer Vaccines: Adjuvants incorporated into cancer vaccines to stimulate immune responses against tumor-specific antigens, potentially leading to tumor regression or prevention of cancer recurrence.
Autoimmune Disease Vaccines: Adjuvants utilized in vaccines targeting autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus, aiming to modulate immune responses and induce tolerance to self-antigens.

Human Vaccine Adjuvants Market, By Geographic

North America: A significant market for human vaccine adjuvants, driven by high healthcare spending, extensive vaccination programs, and strong research and development activities in the pharmaceutical and biotechnology sectors.
Europe: Europe has a robust market for vaccine adjuvants, supported by the presence of leading vaccine manufacturers, government initiatives to promote immunization, and growing demand for novel adjuvant technologies.
Asia-Pacific: Emerging as a key market for human vaccine adjuvants, fueled by increasing awareness of preventive healthcare, rising incidence of infectious diseases, and expanding vaccine manufacturing capabilities in countries like China and India.
Latin America, Middle East, and Africa: These regions are witnessing growing investments in healthcare infrastructure, vaccination campaigns, and disease prevention efforts, driving demand for human vaccine adjuvants to improve vaccine efficacy and public health outcomes.

Key Players

The major players in the Human Vaccine Adjuvants Market are:
GlaxoSmithKline plc
Merck & Co Inc.
Novartis AG
AstraZeneca plc
Bavarian Nordic
Adjuvance Technologies Inc.
Vaxine Pty Ltd.
Dynavax Technologies Corporation

1 INTRODUCTION OF GLOBAL HUMAN VACCINE ADJUVANTS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HUMAN VACCINE ADJUVANTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY TYPE

5.1 Overview
5.2 Aluminum Salts
5.3 Oil-based Adjuvants
5.4 Mineral Salts
5.5 Adjuvant Systems

6 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY APPLICATION

6.1 Infectious Diseases Vaccines
6.2 Cancer Vaccines
6.3 Autoimmune Disease Vaccines

7 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

7.1 Intramuscular (IM) Administration
7.2 Subcutaneous (SC) Administration
7.3 Intradermal (ID) Administration

8 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
8.6 Latin America
8.7 Middle East and Africa

9 GLOBAL HUMAN VACCINE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Serum Institute of India
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Brenntag Biosector
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 CSL Limited
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 SEPPIC
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Agenus, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Novavax, Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 SPI Pharma, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Invivogen
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Avanti Polar Lipids
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 MVP Laboratories
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments